SAR441344 IV, SAR441344 SC — catalyst calendar
Upcoming
| Date | Event | Company | Drug | Official source & verification |
|---|---|---|---|---|
| 2026-07-10 in 18d
ESTIMATED |
READOUT
Efficacy and Safety of Frexalimab (SAR441344) in the Treatment of Systemic Lupus
Phase 2 · Systemic Lupus Erythematosus |
SNY Sanofi | SAR441344 IV, SAR441344 SC |
ClinicalTrials.gov ↗
✓ Source-checked 2026-06-22
Sponsor-projected date — can change
|